491 related articles for article (PubMed ID: 24678978)
1. The role of P-glycoprotein in drug resistance in multiple myeloma.
Abraham J; Salama NN; Azab AK
Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
[TBL] [Abstract][Full Text] [Related]
2. Modulation of multidrug resistance in multiple myeloma.
Sonneveld P
Baillieres Clin Haematol; 1995 Dec; 8(4):831-44. PubMed ID: 8845575
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation.
Shustik C; Dalton W; Gros P
Mol Aspects Med; 1995; 16(1):1-78. PubMed ID: 7783568
[No Abstract] [Full Text] [Related]
4. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment.
Pilarski LM; Belch AR
Leuk Lymphoma; 1995 May; 17(5-6):367-74. PubMed ID: 7549827
[TBL] [Abstract][Full Text] [Related]
6. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.
Muz B; Kusdono HD; Azab F; de la Puente P; Federico C; Fiala M; Vij R; Salama NN; Azab AK
Leuk Lymphoma; 2017 Dec; 58(12):2916-2925. PubMed ID: 28509582
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Binkhathlan Z; Lavasanifar A
Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
[TBL] [Abstract][Full Text] [Related]
8. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study.
Ivy SP; Olshefski RS; Taylor BJ; Patel KM; Reaman GH
Blood; 1996 Jul; 88(1):309-18. PubMed ID: 8704189
[TBL] [Abstract][Full Text] [Related]
9. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
O'Connor R; Ooi MG; Meiller J; Jakubikova J; Klippel S; Delmore J; Richardson P; Anderson K; Clynes M; Mitsiades CS; O'Gorman P
Cancer Chemother Pharmacol; 2013 May; 71(5):1357-68. PubMed ID: 23589314
[TBL] [Abstract][Full Text] [Related]
10. The role of ABC transporters in clinical practice.
Leonard GD; Fojo T; Bates SE
Oncologist; 2003; 8(5):411-24. PubMed ID: 14530494
[TBL] [Abstract][Full Text] [Related]
11. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
Zhou SF
Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
[TBL] [Abstract][Full Text] [Related]
12. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
[TBL] [Abstract][Full Text] [Related]
13. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G
Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976
[TBL] [Abstract][Full Text] [Related]
14. Is resistance useless? Multidrug resistance and collateral sensitivity.
Hall MD; Handley MD; Gottesman MM
Trends Pharmacol Sci; 2009 Oct; 30(10):546-56. PubMed ID: 19762091
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.
Tsuruo T; Naito M; Tomida A; Fujita N; Mashima T; Sakamoto H; Haga N
Cancer Sci; 2003 Jan; 94(1):15-21. PubMed ID: 12708468
[TBL] [Abstract][Full Text] [Related]
17. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
18. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance: genes, polymorphisms, biologic effects, reversal and treatment in cancer chemotherapy.
Aragon-Ching JB
Anticancer Agents Med Chem; 2010 Oct; 10(8):582. PubMed ID: 21244347
[No Abstract] [Full Text] [Related]
20. Relevance of multidrug resistance in the age of targeted therapy.
Türk D; Szakács G
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
